Detalhe da pesquisa
1.
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
J Antimicrob Chemother
; 77(4): 1155-1165, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016205
2.
Protection of the Human Gut Microbiome From Antibiotics.
J Infect Dis
; 217(4): 628-636, 2018 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186529
3.
Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers.
Clin Pharmacol Ther
; 109(4): 1045-1054, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32617960
4.
Microbiota-based markers predictive of development of Clostridioides difficile infection.
Nat Commun
; 12(1): 2241, 2021 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33854066
5.
A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(8): 908-917, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434399
6.
Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics.
Nat Commun
; 12(1): 2240, 2021 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33854064
7.
Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Crit Care Med
; 37(11): 2929-38, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19770753
8.
Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.
J Clin Pharmacol
; 55(1): 10-6, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25042595